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To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+)
refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America
(MGFA) post-intervention status of minimal manifestations (MM), we assessed patients’ status
throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia
Gravis) and its open-label extension.
Methods
Patients who completed the REGAIN randomized controlled trial and continued into the open-label
extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-
intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time
points during REGAIN and through week 130 of the open-label study.
Results
A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/
eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients
than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%;
commonOR: 2.3; 95%CI: 1.1–4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved
improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was
consistent with its known profile and no new safety signals were detected.
Conclusion
Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG.
These findings support the use of eculizumab in this previously difficult-to-treat patient population.
ClinicalTrials.gov Identifier
REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624.
Classification of Evidence
This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with
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In most patients with myasthenia gravis (MG), the disease is
managed using immunosuppressive therapies (ISTs); how-
ever, 10%–15% of patients do not respond adequately to ISTs,
experience intolerable adverse events, or require maintenance
IV immunoglobulin or plasma exchange treatment.1–3 These
patients are considered to have refractory MG, which can
severely affect their health-related quality of life and increase
the socioeconomic burden of the disease.4
There is a consensus that the treatment goal for patients with
generalized MG (gMG) should be achievement of a Myas-
thenia Gravis Foundation of America (MGFA) post-
intervention status of minimal manifestations (MM), de-
fined as having no symptoms indicating functional limitations,
or better.3,5,6
Eculizumab (Soliris, Alexion Pharmaceuticals, Boston, MA) is
a humanized monoclonal antibody that specifically binds and
inhibits cleavage of human terminal complement protein C5.7
The 6-month, phase 3, randomized, placebo-controlled
REGAIN study (Safety and Efficacy of Eculizumab in Anti-
acetylcholine Receptor-Positive [AChR+] Refractory Gener-
alizedMyasthenia Gravis) demonstrated the efficacy and safety
of eculizumab in patients with AChR+ refractory gMG.8 An
interim analysis of the REGAIN open-label extension results
found that eculizumab’s benefits for this population were
maintained through 3 years of treatment.9 MGFA post-
intervention status was assessed as a tertiary endpoint in these
studies. At the date of the open-label study interim analysis,
74.1% of patients had an MGFA post-intervention status of
improved, and 56.0%were considered to have achievedMMor
pharmacologic remission (PR).9 We report a detailed evalua-
tion of final data from the open-label study on patients’ re-
sponse to eculizumab treatment during REGAIN and up to
open-label week 130 using MGFA post-intervention status.
Methods
Standard Protocol Approvals, Registrations,
and Patient Consents
All patients provided written, informed consent. Independent
ethics committees or institutional review boards provided
written approval for the study protocols and all amendments.
The studies were performed in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki and
are registered with clinicaltrials.gov (identifiers: for REGAIN,
NCT01997229; for the REGAIN open-label extension,
NCT02301624).
Study Design and Participants
REGAIN was a 6-month, phase 3, randomized, placebo-
controlled study of eculizumab in patients aged 18 years or
older with AChR+ refractory gMG.8 Patients who completed
REGAIN were eligible for inclusion in the open-label study
and were required to enroll within 2 weeks of completing
REGAIN.9 Patients were eligible for inclusion in REGAIN if
they had confirmed gMG, AChR+ serology, and aMyasthenia
Gravis Activities of Daily Living (MG-ADL) total score of at
least 6, and had received 2 or more ISTs, or at least 1 IST with
IV immunoglobulin or plasma exchange treatment at least 4
times in 12 months without symptom control. Patients with
ocular MG (MGFA Class I) or myasthenic crisis at screening
(MGFA Class V) were excluded from the trial. Full eligibility
criteria have been published previously.8 All participants were
required to have been vaccinated againstNeisseria meningitidis
at least 2 weeks before starting study treatment; individuals
who were not vaccinated at the appropriate time received
prophylactic antibiotics until 2 weeks after vaccination. Dur-
ing the open-label study, patients were revaccinated according
to local guidelines in the country where they were treated, all
of which recommended revaccination after 2–5 years to
maintain active coverage. During REGAIN, patients who
previously received ISTs were required to maintain their
prestudy dose and schedule. During the open-label study,
modifications to IST dose and schedule were permitted at the
discretion of the investigator; however, changes were not
required by the protocol.
Dosing of Eculizumab
In REGAIN, patients randomized to receive eculizumab were
given an induction dose of 900 mg on day 1 and at weeks 1, 2,
and 3, followed by a maintenance dose of 1,200 mg at week 4
and every 2 weeks thereafter (figure 1).8 Placebo was ad-
ministered on the same schedule. Patients who received
eculizumab during REGAIN continued to receive it during
the open-label study (eculizumab/eculizumab arm) and those
who received placebo during REGAIN started eculizumab
treatment upon entering the open-label study (placebo/
eculizumab arm).9 To preserve the blinded nature of
REGAIN, patients who continued into the open-label study
underwent a 4-week blinded induction phase (figure 1).
During this phase, patients in the eculizumab/eculizumab
group received eculizumab 1,200 mg on day 1 and at week 2,
and placebo at weeks 1 and 3. Patients in the placebo/
eculizumab group received eculizumab 900 mg on day 1 and
at weeks 1, 2, and 3. All patients were then given open-label
eculizumab 1,200 mg at week 4 and every 2 weeks thereafter
Glossary
AChR+ = anti-acetylcholine receptor-positive; CI = confidence interval; gMG = generalized myasthenia gravis; IST =
immunosuppressive therapy; MG = myasthenia gravis; MG-ADL = Myasthenia Gravis Activities of Daily Living; MGFA =
Myasthenia Gravis Foundation of America; MM = minimal manifestations; OR = odds ratio; PR = pharmacologic remission;
REGAIN = Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis.
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until it was otherwise available to them, for up to a maximum
of 4 years. The extension study was completed with final
database lock in January 2019.
Assessments
The objectives of REGAIN and the open-label study were to
assess the efficacy of eculizumab, as measured by change in
MG-ADL total score from baseline, and to evaluate its safety.
This analysis assessed the tertiary endpoint of MGFA post-
intervention status and safety data during REGAIN and the
open-label study for patients who continued into the open-
label study.
MGFA post-intervention status can be used to evaluate
changes in a patient’s condition following treatment, in-
cluding improvement, worsening, or no change of clinical
manifestations from pretreatment.6 MGFA post-intervention
status following administration of eculizumab or placebo
during REGAIN, including achievement of MM, was assessed
at weeks 4, 12, and 26 of REGAIN and weeks 26, 40, 52, 78,
104, and 130 of the open-label study and was based on
comparison with patients’ disease state before REGAIN.
MGFA post-intervention status was reported as improved if a
patient’s pretreatment clinical manifestations were sub-
stantially decreased, worse if they were substantially increased,
or unchanged if they were not substantially changed com-
pared with REGAIN baseline. In this analysis, the group of
patients with improved status included patients who achieved
MM or PR. In patients with improved status, MM was ach-
ieved if they had no symptoms indicating functional limita-
tions from MG but had some weakness on examination of
some muscles.6 Subcategories of MM relating to treatment
status were not assessed. Patients were evaluated for PR at
open-label study weeks 26, 40, 52, 78, 104, and 130. PR was
achieved if patients had no signs or symptoms of MG for at
least 1 year and, upon examination, had no weakness of any
muscle, other than isolated weakness of eyelid closure.
Daily doses of corticosteroids, azathioprine, and mycophe-
nolate mofetil were recorded throughout the open-label
study.
Adverse events were recorded and coded by preferred term
using the Medical Dictionary for Regulatory Activities Ver-
sion 20.1. MG exacerbations, use of rescue therapy, and study
discontinuations because of adverse events were also
recorded.
Statistical Analysis
Patients who were not assessed for MGFA post-intervention
status at a particular time point were not included in the
analysis for that time point.
The common odds ratio (OR) and the associated 95% con-
fidence intervals (CIs) for achievement of improved status or
MM at REGAIN week 26 for patients who received eculizu-
mab compared with those who received placebo were calcu-
lated using an ordinal logistic regression model with MGFA
post-intervention status (achieved MM, improved but MM
not achieved, unchanged, or worse) as a dependent variable,
and treatment group as an independent variable.
For between-group comparisons, 95% CIs of the differences
in means were based on the t-distribution for continuous
variables. Within a single treatment group, 95% CIs were
calculated using the Clopper-Pearson method.
Figure 1 Study Design
aDuring the blinded induction phase of the open-label study, patients received eculizumab (1,200 mg; 4 vials) on day 1 and at week 2 and placebo (4 vials) at
weeks 1 and 3 (eculizumab/eculizumab group), or placebo (1 vial) plus eculizumab (900 mg; 3 vials) each week (placebo/eculizumab group). bPatients who
withdrew fromor discontinued participation in the study after receiving any amount of eculizumabwere required to complete a safety follow-up visit 8 weeks
after their last eculizumab dose. REGAIN = Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia
Gravis; SOC = standard of care. Figure reproduced with permission (creativecommons.org/licenses/by-nc/4.0/) from Muppidi et al.9
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All statistical analyses were performed using SAS software
version 9.4 (SAS Institute, Cary, NC).
Classification of Evidence
The primary research question of this analysis of data from the
6-month, phase 3, randomized, placebo-controlled REGAIN
study and its open-label extension was whether adults with
AChR+ refractory gMG could achieve an MGFA post-
intervention status of MM with eculizumab therapy.
This study provides Class II evidence that, in this previously
difficult-to-treat patient population, after 26 weeks of treat-
ment during REGAIN, a greater proportion treated with
eculizumab than placebo achieved an MGFA post-
intervention status of MM (25.0% vs 13.3%; common OR
2.3; 95% CI 1.1–4.5). After 130 weeks of eculizumab therapy,
most patients (57.3%) achieved MM status.
Data Availability
Alexion will consider requests for disclosure of clinical study
participant-level data provided that participant privacy is as-
sured through methods like data de-identification, pseudo-
nymization, or anonymization (as required by applicable law),
and if such disclosure was included in the relevant study in-
formed consent form or similar documentation. Qualified
academic investigators may request participant-level clinical
data and supporting documents (statistical analysis plan and
protocol) pertaining to Alexion-sponsored studies. Further
details regarding data availability and instructions for
requesting information are available in the Alexion Clinical
Trials Disclosure and Transparency Policy at alexion.com/
research-development. The data request form is available at
alexion.com/contact-alexion/medical-information.
Results
Patient Demographics and Characteristics
A total of 117 patients who completed REGAIN continued
into the open-label study (eculizumab/eculizumab: 56;
placebo/eculizumab: 61; figure 2) and were included in the
efficacy and safety analysis. Patient demographics and char-
acteristics, published previously, were similar for the
eculizumab/eculizumab and placebo/eculizumab groups,
with the exception that there was a greater proportion of
Asian patients in the placebo/eculizumab group.9
The open-label extension study was completed with a final
database lock in January 2019. At study completion, patients
had participated in the study for different periods of time. A
total of 87 patients completed the study (eculizumab/
eculizumab: 43; placebo/eculizumab: 44; figure 2). Of
these, 71 patients (eculizumab/eculizumab: 35; placebo/
eculizumab: 36) had received open-label eculizumab for at
least 130 weeks by the end of the study.
MGFA Post-intervention Status During REGAIN
and the Open-Label Study
During REGAIN, at all time points assessed, a higher pro-
portion of patients who received eculizumab than of those
who were given placebo achieved improved status (table 1
and figure 3). At week 4, 54.5% of eculizumab-treated patients
(30/55) achieved a status of improved compared with 24.6%
Figure 2 Patient Disposition in REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Re-
fractory Generalized Myasthenia Gravis) and the Open-Label Study
ECU = eculizumab; PLC = placebo. Figure reproduced with permission (creativecommons.org/licenses/by/4.0/) from Vissing et al.13
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of placebo-treated patients (15/61). At week 26, 60.7% of
eculizumab-treated patients (34/56) had achieved a status of
improved, compared with 41.7% of placebo-treated patients
(25/60). One patient who received eculizumab had a status of
worse at week 26 compared with 5 individuals who received
placebo. By week 130 of the open-label study, most patients in
both groups had achieved improved status: 80.0% of partici-
pants in the eculizumab/eculizumab group (28/35) and
94.3% of those in the placebo/eculizumab group (33/35; 1
patient did not complete the assessment). Of the 117 patients
enrolled in the open-label extension study, 113 were assessed
for MGFA post-intervention status at their last assessment:
71.4% of patients in the eculizumab/eculizumab group (40/
56) and 82.5% of those in the placebo/eculizumab group (47/
57) achieved improved status.
During REGAIN, the proportion of patients receiving eculi-
zumab who achieved MM increased from 18.2% (10/55) at
week 4 to 25.0% (14/56) at week 26 (table 1 and figure 3).
MM status was achieved by a smaller proportion of the pla-
cebo group (8.2% [5/61] at week 4 and 13.3% [8/60] at week
26) than of the eculizumab group. Eculizumab-treated
patients were more likely to achieve a status of improved or
MM at REGAIN week 26 than those given placebo (common
OR 2.3; 95% CI 1.1–4.5). By week 130 of the open-label
study, the proportion of patients achieving MM had increased
to 51.4% in the eculizumab/eculizumab group (18/35) and to
62.9% in the placebo/eculizumab group (22/35). At last as-
sessment, MM was achieved by 41.1% of patients in the
eculizumab/eculizumab group (23/56) and 54.4% of patients
in the placebo/eculizumab group (31/57).
Patients in the eculizumab/eculizumab and placebo/
eculizumab groups received eculizumab for different periods
of time during REGAIN and its open-label extension; of all
patients who received eculizumab for 26 weeks (eculizumab/
eculizumab group to week 26 of REGAIN and placebo/
eculizumab group to week 26 of the open-label study), most
(66.1%; 74/112) achieved improved status and over one-third
(36.6%; 41/112) achieved MM status (table 2). Almost one-
third of participants (32.1%; 36/112) had a status of un-
changed and 2 patients had a status of worse after 26 weeks’
eculizumab therapy (table 2). The proportions of patients
who achieved improved or MM status increased with
Table 1 Change in Myasthenia Gravis Foundation of America Post-intervention Status From REGAIN (Safety and Efficacy
of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Baseline
During REGAIN and Its Open-Label Extension by Treatment Group
Study Visita






























































































































































































Abbreviations: CI = confidence interval; MM = minimal manifestations.
a Weeks are numbered separately for REGAIN (0–26) and the open-label study (0–130).
b At the time of study completion, patients had participated for different periods of time. The numbers of patients at each time point reflect this and also
account for discontinuations and for patients who did not complete the assessment at the specified time point.
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continued eculizumab treatment: 88.0% (66/75) of those
who received eculizumab for 130 weeks achieved improved
status and 57.3% (43/75) achieved MM status (table 2). In
addition, 2 patients achieved PR after 130 weeks of eculizu-
mab therapy. At last assessment, 77.0% of patients (87/113)
achieved improved status and 47.8% (54/113) achieved MM
status (table 2).
There were no differences in mean age (46.5 vs 47.4 years; dif-
ference−0.9; 95%CI−7.6 to 5.8) ormean disease duration (9.3 vs
Figure 3 Patients Who AchievedMyasthenia Gravis Foundation of America Post-intervention Status of Improved orMinimal
Manifestations at REGAIN (Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory
Generalized Myasthenia Gravis) Weeks 4, 12, and 26, and Open-Label Study Weeks 26, 52, 78, 104, and 130
aWeeks are numbered separately for
REGAIN (0–26) and the open-label
study (0–130). bAt the time of study
completion, patients had participated
for different periods of time. The
numbers of patients at each timepoint
reflect this and also account for dis-
continuations and for patients whodid
not complete the assessment at the
specified time point.
Table 2 Change in Myasthenia Gravis Foundation of America Post-intervention Status from REGAIN (Safety and Efficacy
of Eculizumab in Anti-acetylcholine Receptor-Positive Refractory Generalized Myasthenia Gravis) Baseline by
Eculizumab Treatment Duration
Duration of eculizumab treatment, wk Improved MM Unchanged Worse
26 74/112 (66.1) [56.5–74.7] 41/112 (36.6) [27.7–46.2] 36/112 (32.1) [23.6–41.6] 2/112 (1.8) [0.2–6.3]
52 80/102 (78.4) [69.2–86.0] 53/102 (52.0) [41.8–62.0] 22/102 (21.6) [14.0–30.8] 0/102 (0.0) [0.0–3.6]
78 83/96 (86.5) [78.0–92.6] 51/96 (53.1) [42.7–63.4] 11/96 (11.5) [5.9–19.6] 2/96 (2.1) [0.3–7.3]
104 71/84 (84.5) [75.0–91.5] 44/84 (52.4) [41.2–63.4] 11/84 (13.1) [6.7–22.2] 2/84 (2.4) [0.3–8.3]
130 66/75 (88.0) [78.4–94.4] 43/75 (57.3) [45.4–68.7] 8/75 (10.7) [4.7–19.9] 1/75 (1.3) [0.0–7.2]
Last assessment 87/113 (77.0) [68.1–84.4] 54/113 (47.8) [38.3–57.4] 22/113 (19.5) [12.6–28.0] 4/113 (3.5) [1.0–8.8]
Abbreviation: MM = minimal manifestations.
At the time of study completion, patients had participated for different periods of time. The numbers of patients listed for each treatment duration reflect this
and also account for discontinuations and for patients who did not complete the assessment at the specified time point. Values are n/N (%) [95% confidence
interval].
Neurology.org/N Neurology | Volume 96, Number 4 | January 26, 2021 e615
10.3 years; difference −1.0; 95% CI −4.2 to 2.2) between
eculizumab-treated patients who achievedMM status up to open-
label study week 130 (n = 76) and those who did not (n = 37).
Among the 76 eculizumab-treated patients who achieved MM
status up to open-label study week 130, 58 (76.3%) were using
corticosteroids, 29 (38.2%) were using azathioprine, and 16
(21.1%)were usingmycophenolatemofetil at open-label baseline.
The mean daily doses of ISTs used by patients who first
achieved MM status during the open-label study decreased
between open-label baseline and last reported dose before
first achieving MM status. In those using each IST at open-
label baseline, the mean daily doses of corticosteroids, aza-
thioprine, and mycophenolate mofetil decreased by 18.7%,
26.0%, and 16.0%, respectively (table 3).
Safety
Safety data have previously been published for REGAIN and
the interim analysis of the open-label study.8,9 Across these 2
studies, the most common adverse events with eculizumab for
patients included in this analysis were headache and naso-
pharyngitis, which were experienced by 44.4% and 38.5% of
patients, respectively (table 4). Serious adverse events of
worsening of MG and MG crisis occurred in 15.4% and 3.4%
of patients, respectively. MG exacerbations were experienced
by 29.1% of patients, and 25.6% used rescue therapy. During
REGAIN and the open-label study, 11 patients discontinued
because of an adverse event, and 3 deaths occurred, which
were all considered likely to be related to comorbidities
(figure 2).9 There were 16 patients who withdrew themselves
from REGAIN or the open-label study, 6 patients who were
withdrawn by their physician, and 1 patient who discontinued
for “other” reasons; no further information was collected re-
garding the reasons for these discontinuations.
Discussion
This analysis found that patients with AChR+ refractory gMG
treated with eculizumab experienced rapid improvements in
their clinical condition based on MGFA post-intervention
status. Over 50% of patients achieved a status of improved
within 4 weeks of their first dose of eculizumab in REGAIN
and one-third of these patients also achieved MM. By
REGAIN week 26, significantly higher proportions of
eculizumab-treated patients than placebo-treated patients
achieved an MGFA post-intervention status of improved
or MM.
Long-term eculizumab treatment was associated with further
increases in the proportions of patients who achieved a status of
improved or MM. After 130 weeks of eculizumab therapy, al-
most 90% of patients remaining in the study had attained a status
of improved and nearly 60% had achieved MM. Notably, in
patients who achieved MM status during the open-label study,
mean daily doses of concomitant ISTs were reduced before they
first achievedMM. These findings suggest that for some patients
with AChR+ refractory gMG, long-term treatment with eculi-
zumab is beneficial for optimal disease control. Furthermore, 2
patients achieved PR after 130 weeks of eculizumab treatment,
reflecting long-term maintenance of symptom relief.
The long-term safety profile of eculizumab was consistent
with its known profile from over 10 years of clinical use in
other indications,10–12 and no new safety signals were ob-
served during the open-label study.
The main limitation of this analysis is the open-label design of
the extension study, which could yield unconscious bias to-
wards reporting of positive outcomes with eculizumab. Be-
cause over 90% of patients who enrolled in REGAIN
continued into the open-label study, selection bias in the
open-label study population is unlikely.
The results of this analysis confirm the rapid and sustained clinical
response to eculizumab that was observed during REGAIN and
the open-label study. Over 50% of patients who were considered
to have refractory disease achieved the consensus treatment goal
of MM or better after 1 year of eculizumab treatment. These
findings further support the long-term effectiveness of eculizu-
mab for use in patients with AChR+ refractory gMG.
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Exacerbation 13 (21.3) 77.7 4 (7.1) 35.5 34 (29.1) 23.9
Rescue therapy use 10 (16.4) 68.0 4 (7.1) 35.5 30 (25.6) 22.0
Most common adverse eventsb,c (>15% of all
patients)
Headache 12 (19.7) 90.6 10 (17.9) 88.7 52 (44.4) 32.8
Nasopharyngitis 10 (16.4) 42.1 9 (16.1) 46.1 45 (38.5) 32.1
Diarrhea 8 (13.1) 29.1 8 (14.3) 35.5 33 (28.2) 17.4
Upper respiratory tract infection 12 (19.7) 45.3 9 (16.1) 46.1 31 (26.5) 25.2
Nausea 9 (14.8) 84.1 7 (12.5) 35.5 27 (23.1) 12.1
Myasthenia gravisd 9 (14.8) 58.3 4 (7.1) 14.2 30 (25.6) 17.4
Arthralgia 5 (8.2) 29.1 1 (1.8) 3.5 24 (20.5) 10.5
Pain in extremity 2 (3.3) 6.5 4 (7.1) 14.2 20 (17.1) 8.5
Urinary tract infection 5 (8.2) 22.7 3 (5.4) 14.2 20 (17.1) 12.5
Most common myasthenia gravis– and
infection-related serious adverse eventsb,c (≥2
patients)
Myasthenia gravisd 6 (9.8) 45.3 3 (5.4) 10.6 18 (15.4) 10.5
Pyrexia 0 (0.0) 0.0 2 (3.6) 7.1 5 (4.3) 1.6
Myasthenia gravis crisis 0 (0.0) 0.0 0 (0.0) 0.0 4 (3.4) 1.3
Acute respiratory failure 0 (0.0) 0.0 0 (0.0) 0.0 3 (2.6) 1.0
Gastroenteritis 1 (1.6) 9.7 0 (0.0) 0.0 3 (2.6) 1.0
Pneumonia 0 (0.0) 0.0 0 (0.0) 0.0 4 (3.4) 1.6
Sepsis 0 (0.0) 0.0 0 (0.0) 0.0 3 (2.6) 1.0
Bronchitis 0 (0.0) 0.0 0 (0.0) 0.0 2 (1.7) 1.0
Urinary tract infection 0 (0.0) 0.0 0 (0.0) 0.0 2 (1.7) 1.0
Influenza 0 (0.0) 0.0 0 (0.0) 0.0 2 (1.7) 0.7
Upper respiratory tract infection 2 (3.3) 6.5 0 (0.0) 0.0 2 (1.7) 0.7
Pneumonia aspiration 0 (0.0) 0.0 0 (0.0) 0.0 2 (1.7) 0.7
Localized infection 0 (0.0) 0.0 0 (0.0) 0.0 2 (1.7) 0.7
Abbreviation: PY = patient-year.
a PY is the sum of all years for all patients and the observed event rate is the number of events per PY multiplied by 100.
b Medical Dictionary for Regulatory Activities preferred term.
c If a patient had more than 1 adverse event for a particular preferred term, that patient is counted only once for that preferred term.
d Worsening (increased frequency and/or intensity) of a preexisting condition, including myasthenia gravis, is considered to be an adverse event.
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Appendix 2 Coinvestigators
Coinvestigators are listed at links.lww.com/WNL/B275
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